Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients

Neuroscience Letters

Volumn 259, Issue 3, 1999, Pages 196-198

  Schwarz, Marcus J ^a   Späth, Michael ^a   Müller Bardorff, Hanns ^a   Pongratz, Dieter E ^a   Bondy, Brigitta ^a   Ackenheil, Manfred ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

5 Hydroxyindoleacetic acid; 5 Hydroxytryptamine; Fibromyalgia; Pain; Serotonin; Sleep; Substance P; Tryptophan

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; SEROTONIN; SUBSTANCE P; TRYPTOPHAN;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; FIBROMYALGIA; HUMAN; MALE; NEUROTRANSMITTER RELEASE; PAIN; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SLEEP DISORDER;

EID: 0344938405     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(98)00937-9     Document Type: Article

References (22)

1. Edvinsson L., Ekman R., Jansen I., Ottosson A., Uddman R. Peptide-containing nerve fibers in human cerebral arteries: immunocytochemistry, radioimmunoassay, and in vitro pharmacology. Ann. Neurol. 21:1987;431-437.
2. Eide P.K., Hole K. Interactions between serotonin and substance P in the spinal regulation of nociception. Brain Res. 550:1991;225-230.
3. Heils A., Teufel A., Petri S., Stober G., Riederer P., Bengel D., Lesch K.P. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66:1996;2621-2624.
4. Hornfeldt C.S., Sun X., Larson A.A. The NH2-terminus of substance P modulates NMDA-induced activity in the mouse spinal cord. J. Neurosci. 14:1994;3364-3369.
5. Hrycaj P., Stratz T., Muller W. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome (letter; comment). J. Rheumatol. 20:1993;1986-1988.
6. Larson A.A., Igwe O.J., Seybold V.S. Effects of lysergic acid diethylamide (LSD) and adjuvant-induced inflammation on desensitization to and metabolism of substance P in the mouse spinal cord. Pain. 37:1989;365-373.
7. Liu Z., Welin M., Bragee B., Nyberg F. Elevated substance P levels are contrasted by a decrease in Met-enkephalin-Arg-Phe in CSF from fibromyalgia patients. Analgesia. 4(6):1995;543-547.
8. Malmberg A.B., Yaksh T.L. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science. 257:1992;1276-1279.
9. Markenson J.A. Mechanisms of chronic pain. Am. J. Med. 101:1996;6S-18S.
10. Moldofsky H. Rheumatic pain modulation syndrome: the interrelationships between sleep, central nervous system serotonin, and pain. Adv. Neurol. 33:1982;51-57.
11. Murphy R.M., Zemlan F.P. Differential effects of substance P on serotonin-modulated spinal nociceptive reflexes. Psychopharmacology (Berl.). 93:1987;118-121.
12. Naranjo J.R., Arnedo A., Molinero M.T., Del R.J. Involvement of spinal monoaminergic pathways in antinociception produced by substance P and neurotensin in rodents. Neuropharmacology. 28:1989;291-298.
13. Reynolds W.J., Chiu B., Inman R.D. Plasma substance P levels in fibrositis. J. Rheumatol. 15:1988;1802-1803.
14. Russell I.J. Advances in fibromyalgia: possible role for central neurochemicals. Am. J. Med. Sci. 315:1998;377-384.
15. Russell I.J., Michalek J.E., Vipraio G.A., Fletcher E.M., Javors M.A., Bowden C.A. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome (see comments). J. Rheumatol. 19:1992;104-109.
16. Russell I.J., Orr M.D., Littman B., Vipraio G.A., Alboukrek D., Michalek J.E., Lopez Y., MacKillip F. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 37:1994;1593-1601.
17. Sharma H.S., Nyberg F., Olsson Y., Dey P.K. Alteration of substance P after trauma to the spinal cord: an experimental study in the rat. Neuroscience. 38:1990;205-212.
18. Stratz T., Samborski W., Hrycaj P., Pap T., Mackiewicz S., Mennet P., Muller W. Serotonin concentration in serum of patients with generalized tendomyopathy (fibromyalgia) and chronic polyarthritis. Med. Klin. 88:1993;458-462.
19. Vaeroy H., Helle R., Forre O., Kass E., Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain. 32:1988;21-26.
20. Walker P.D., Riley L.A., Hart R.P., Jonakait G.M. Serotonin regulation of tachykinin biosynthesis in the rat neostriatum. Brain Res. 546:1991;33-39.
21. Wolfe F., Russell I.J., Vipraio G., Ross K., Anderson J. Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J. Rheumatol. 24:1997;555-559.
22. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., Tugwell P., Campbell S.M., Abeles M., Clark P., Fam A.G., Farber S.J., Fiechtner J.J., Franklin C.M., Gatter R.A., Hamaty D., Lessrad J., Lichtbroun A.S., Masi A.T., McCain G.A., Reynolds W.J., Romano T.J., Russell I.J., Sheon R.P. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 33:1990;160-172.